Erythromycin

C difficile risk
Low
Oral Bioavailability
Moderate

Dosing

Defined criteria for use and/or important safety considerations. See below for more information.

General Information

For most indications, azithromycin or clarithromycin are preferred Motility agent

Monitor QTc in patients with increased risk

  • Nausea/vomiting (25%)

  • Diarrhea (8%)

  • Prolonged QT interval and Torsades de Pointes

  • Substrate of CYP3A4. Multiple CYP450 interactions possible

  • Caution with QTc prolonging medications

  • May increase digoxin and carbemazepine levels

  • Statins: risk rhabdomyolysis

Antimicrobial Class: Macrolide

Route of Elimination: Primarily hepatic

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.